Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

Comparative clinical study of depigmentation products on facial melasma in Latin women

Show simple item record

dc.contributor.author Orlandi-Jorquera, Cecilia
dc.contributor.author Moran-Cardenas, María Gabriela
dc.contributor.author Escobar-Huenchul, Valery Magdalena
dc.date.accessioned 2019-06-24T22:33:02Z
dc.date.available 2019-06-24T22:33:02Z
dc.date.issued 2016
dc.identifier.citation ORLANDI-JORQUERA, Cecilia, MORAN-CARDENAS, María Gabriela, ESCOBAR-HUENCHUL, Valery Magdalena. Comparative clinical study of depigmentation products on facial melasma in Latin women. In: Curierul Medical. 2016, vol. 59, no 4, pp. 29-32. ISSN 1875-0666.
dc.identifier.issn 1857-0666
dc.identifier.uri http://moldmedjournal.md/wp-content/uploads/2016/09/Cm-4-2016-PDF.pdf
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/2933
dc.description.abstract Background: Hyperpigmented lesions need the most frequent dermatological consultations, the acquired ones being more effectively treated. Out of them, the most common is melasma, which is currently treated with hydroquinone. Our objective was to compare the efficacy of a treatment based on Diacetylboldine-DAB, Alpha arbutin and Licorice with hydroquinone 4%. Material and methods: We carried out a pilot study on 30 Latin patients (skin type III and IV after Fitzpatrick’s classification). The product under study was applied on one side of the face and hydroquinone on the other, during 60 days. Results: The study product demonstrated effectiveness comparable to 4% hydroquinone in the 60 days of monitoring time. The hyperpigmentations are of a chronic type and so, considering the formula of the study product, it has the great advantage of permitting use for a prolonged period of time without the risk of undesirable side effects such as ochronosis. Tolerance for the product was excellent as well, both for daytime and night-time formulations, and neither irritation reactions nor allergic reactions were present during the period of use. Conclusions: The combined use of active substances is similar and comparable to hydroquinone in a 60 day period. The foundation can be laid for future studies to approach a new investigation with a larger number of patients, in which the use of hydroquinone can be established in comparison with this new treatment, so as to allow a statistically significant relationship to be established. Additionally, by studying a larger number of participants, it would allow this new product to be set up as an effective alternative treatment for melasma. en_US
dc.language.iso en en_US
dc.publisher Ministerul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” en_US
dc.relation.ispartof Curierul Medical
dc.subject facial melasma en_US
dc.subject antipigment skin agents en_US
dc.subject.mesh Melanosis--drug therapy en_US
dc.subject.mesh Facial Dermatoses--drug therapy en_US
dc.subject.mesh Skin Pigmentation--drug effects en_US
dc.subject.mesh Hydroquinones--therapeutic use en_US
dc.title Comparative clinical study of depigmentation products on facial melasma in Latin women en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics